Drug Trial Radar · NCT00622349
Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Jan 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
707
Actual
Start
Feb 2004
Primary completion
Mar 2009
Study completion Dec 2009
Sponsor
- Lead sponsor
- European Lung Cancer Working PartyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 25, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if cisplatin-based chemotherapy, cisplatin-gemcitabine-ifosfamide or cisplatin-docetaxel, will improve survival in comparison to the combination gemcitabine-ifosfamide in patients with advanced NSCLC
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
Cisplatin, Ifosfamide, GemcitabineDrug
Cisplatin 50 mg/m² day 1 Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
Ifosfamide, GemcitabineDrug
Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
Cisplatin, docetaxelDrug
Cisplatin 50 mg/m² day 1 Docetaxel 75 mg/m² day 1 Cycles every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- SurvivalTime frame: Survival will be dated from the first day of registration until death or last follow up
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet
Brussels, Belgium
Pneumology department of CHU Lille
Lille, France
Hellenic Cancer Institute - St Savas Oncology Hospital
Athens, Greece
Medical Oncology Hospital de Sagunto
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.